Drug Profile
Exenatide/insulin - Oramed
Alternative Names: ORMD 0801/ORMD 0901Latest Information Update: 27 May 2022
Price :
$50
*
At a glance
- Originator Oramed Pharmaceuticals
- Class Antihyperglycaemics; Glucagon-like peptides; Insulins; Pancreatic hormones; Peptides; Venoms
- Mechanism of Action Glucagon like peptide 1 receptor agonists; Insulin receptor agonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 24 May 2022 Oramed Pharmaceuticals has patent protection for insulin/exenatide oral combination for Diabetes mellitus in USA
- 07 Apr 2020 Oramed Pharmaceuticals receives patent allowance Methods and Compositions for Oral Administration of Proteins in Canada
- 28 Feb 2019 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in Israel (PO, Capsule)